Literature DB >> 1772649

Normal human serum depleted of C1q, factor D and properdin: its use in studies of complement activation.

A G Sjöholm1, B Selander, S Ostenson, E Holmström, C Söderström.   

Abstract

Normal human sera were depleted of C1q, factor D (D) and properdin (P) by a simple and reproducible procedure providing reagents for analysis of complement-dependent functions. Classical pathway activity was restored with purified C1q, and alternative pathway activity with purified D and P. Since both activation pathways were abolished, antibodies and other components could be removed without loss of complement activity during immunoabsorption procedures. Synergism between the two pathways during haemolysis of rabbit erythrocytes was clearly demonstrated, and was also found on analysis of C3 cleavage in serum incubated with other alternative pathway activators such as zymosan and inulin. Experiments with a Neisseria meningitidis serogroup W-135 strain isolated from a patient with inherited P deficiency showed that both pathways were capable of supporting antibody-dependent killing of the bacteria in serum. The alternative pathway was possibly more efficient than the classical pathway in the assay system. In C1q,D,P-depleted serum with high concentrations of anticapsular IgG antibodies, the addition of D alone resulted in efficient alternative pathway-mediated killing. The alternative pathway was equally efficient in a C1q,D,P-depleted serum with low concentrations of anticapsular antibody, but in this case the reaction required both D and P.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1772649     DOI: 10.1111/j.1699-0463.1991.tb01309.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  7 in total

1.  Streptococcus pyogenes Endopeptidase O Contributes to Evasion from Complement-mediated Bacteriolysis via Binding to Human Complement Factor C1q.

Authors:  Mariko Honda-Ogawa; Tomoko Sumitomo; Yasushi Mori; Dalia Talat Hamd; Taiji Ogawa; Masaya Yamaguchi; Masanobu Nakata; Shigetada Kawabata
Journal:  J Biol Chem       Date:  2017-01-30       Impact factor: 5.157

2.  Vaccination responses to capsular polysaccharides of Neisseria meningitidis and Haemophilus influenzae type b in two C2-deficient sisters: alternative pathway-mediated bacterial killing and evidence for a novel type of blocking IgG.

Authors:  B Selander; H Käyhty; E Wedege; E Holmström; L Truedsson; C Söderström; A G Sjöholm
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

3.  Properdin deficiency in a large Swiss family: identification of a stop codon in the properdin gene, and association of meningococcal disease with lack of the IgG2 allotype marker G2m(n).

Authors:  P J Späth; A G Sjöholm; G N Fredrikson; G Misiano; R Scherz; U B Schaad; B Uhring-Lambert; G Hauptmann; J Westberg; M Uhlén; C Wadelius; L Truedsson
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

4.  EndoS and SpeB from Streptococcus pyogenes inhibit immunoglobulin-mediated opsonophagocytosis.

Authors:  Mattias Collin; Mikael D Svensson; Anders G Sjöholm; Jens C Jensenius; Ulf Sjöbring; Arne Olsén
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

5.  Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2.

Authors:  Barbro Selander; Ulla Mårtensson; Andrej Weintraub; Eva Holmström; Misao Matsushita; Steffen Thiel; Jens C Jensenius; Lennart Truedsson; Anders G Sjöholm
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

6.  Contribution of chondroitin sulfate A to the binding of complement proteins to activated platelets.

Authors:  Osama A Hamad; Per H Nilsson; Maria Lasaosa; Daniel Ricklin; John D Lambris; Bo Nilsson; Kristina Nilsson Ekdahl
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

7.  Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets.

Authors:  O A Hamad; K N Ekdahl; P H Nilsson; J Andersson; P Magotti; J D Lambris; B Nilsson
Journal:  J Thromb Haemost       Date:  2008-05-22       Impact factor: 5.824

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.